Attempts to expand ex vivo the numbers of human hematopoietic stem cells (HSCs) without compromising their marrow repopulating capacity and their ability to establish multilineage hematopoiesis has been the subject of intense investigation.
| INTRODUCTION
Human hematopoietic stem cells (HSCs) are rare cells, quiescent under steady-state conditions, which express specific phenotypic markers and possess characteristic functional properties. 1 There are several ontological sources of HSCs: fetal liver, fetal marrow, umbilical cord blood (UCB), and adult bone marrow (ABM) or cytokine mobilized peripheral blood (mPB). Each source of HSCs is defined by their own proliferative capacity and their ability to establish multilineage hematopoiesis in myeloablated hosts. [2] [3] [4] Since the number of HSCs present in a single UCB collection is frequently insufficient to repopulate in a timely fashion adult patients with refractory hematological malignancies or genetic disorders involving blood cells, most ex vivo HSC expansion methods have focused on UCB rather than adult sources of HSCs. 5 However, the biological differences that distinguish the different ontological sources of HSCs do not assure that conditions that were effective for UCB-HSC expansion would be equally effective for the adult sources of HSCs. Several studies have indicated that UCB-CD34+ cells expanded ex vivo possess a higher marrow repopulating potential as compared to adult CD34+ cells from either ABM of mPB. 2, 3 In addition, Wang and coworkers reported that UCB contains a higher percentage of cells capable of repopulating NSG mice as compared to HSCs from adult sources. 4 The ability to expand the numbers of adult HSCs and/or preserve their function would be potentially useful as a cellular platform for genetic modification strategies. 6, 7 Our laboratory has utilized the histone deacetylase inhibitor (HDACI)-valproic acid (VPA) to expand the numbers of UCB-HSCs. Treatment of UCB-CD34+ cells with VPA and cytokines for 7 days (after 16 hours of priming with cytokines only) resulted in a significant increase in the numbers of phenotypically defined HSCs. The expanded HSCs were capable of long-term engraftment when assessed in vivo in immune-deficient mice, and lacked malignant potential. 8, 9 We recently reported the preclinical development of a UCB-derived HSC product for allogeneic transplantation for patients with hematological malignancies, 10 and a clinical trial is underway (NCT03885947). In the present study, we applied our UCB expansion approach to granulocyte colony-stimulating factor (G-CSF) mPB and ABM-CD34+ cells from healthy adult donors in order to determine if this same strategy was an effective means of preserving HSCs function.
| MATERIALS AND METHODS

| Ex vivo cultures
Cryopreserved CD34+ cells from mPB or ABM from healthy adult donors were purchased from AllCells (Alameda, California) and stored in liquid nitrogen. The highly purified (90%-98%) CD34+ cells were thawed and cultured in serum-free medium Stemline II (Sigma-Aldrich, St. Louis, Missouri) supplemented with 150 ng/mL human stem cell factor (SCF), 100 ng/mL human fms-like tyrosine kinase receptor 3 (FLT-3-ligand), 100 ng/mL human thrombopoietin (TPO), and 50 ng/mL human interleukin 3 (IL3) (R&D Systems, Minneapolis, Minnesota). Cells were seeded at 3.3 × 10 4 cells/mL in 22.1 mm wells (12-well plates) and incubated in a humidified incubator maintained at 37 C with 5% CO 2 . The cells were incubated with the cytokines alone for 16 hours (cytokine priming) followed by addition of VPA 1 mM (Sigma-Aldrich), then incubated in the presence of VPA and cytokines for additional 7 days ( Figure 1A ). The viability, number of the total nucleated cells (TNC), CD34+ cells, and frequency of various HSC subpopulations were determined shortly after thawing of the primary cells (PCs) and at daily time points, in both VPA-treated cultures and control cultures containing cytokines alone (control).
| Cell counting and viability assay
A Cellometer Auto 2000 Cell Viability Counter (Nexcelom Bioscience, Lawrence, Massachusetts) was used for both cell counting and assessment of cell viability as per the manufacturer's instructions. Cell counting was validated using the trypan blue exclusion method in selected situations: after the thawing of cryopreserved specimens, at early-day time points, and when outlier values were encountered. The fold expansion of a particular cell population was calculated by dividing the total number of nucleated cells recovered at day 7 by the input cell number expressing the identical phenotype.
| Phenotypic analyses
PCs or cultured cells expanded with cytokines in the presence or absence of VPA were stained with the anti-human antibodies 7AAD-PerCP-Cy5, CD34-APC, CD90-FITC, CD49f-PE, and CD45RA-PE-Cy7 or their isotype-matched controls (BD Biosciences, San Jose, California) for 20 minutes in room temperature, washed and analyzed using the FACS-Canto II (BD Biosciences). Analyses were performed with BD FACSDiva Software and FlowJo Software (BD Biosciences).
| Aldehyde dehydrogenase (ALDH) assay
To identify cell populations with high ALDH activity, an Aldefluor kit (StemCell Technologies, Vancouver, Canada) was used according to the manufacturer's instructions. Cells (1 × 10 6 or 0.5 × 10 6 ) were
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This study shows that the transplantation of ex vivo valproic acid (VPA)-treated, adult mobilized peripheral blood and bone marrow hematopoietic stem cells (HSCs) into immunedeficient mice led to nonbiased long-term multilineage hematopoietic cell engraftment including T cells. These data support the use of VPA-mediated ex vivo HSC expansion for future gene modification strategies. suspended in assay buffer, then half of the cells were added to the Aldefluor substrate (test sample) and the remaining half was added to N,N-diethylaminobenzaldehyde (DEAB) inhibitor (control sample). The test and control samples were incubated for 40 minutes at 37 C. Cells were subsequently stained with CD34-APC and CD90-PE mAbs or isotype-matched controls for an additional 20 minutes. Cells were washed and analyzed by flow cytometry using a FACS-Canto II (BD Biosciences).
| Assessment of mitochondrial membrane potential
Mitochondrial membrane potential was measured using tetramethylrhodamine methyl ester (TMRM) (Invitrogen, Carlsbad, California) with or without the efflux pump inhibitor, verapamil. Cells were incubated for 20 minutes at 37 C with 200 nM TMRM. Following washes, the cells were stained with CD34-APC and CD90-FITC in PBS containing 7.5% BSA and 0.5% EDTA for 20 minutes at room temperature, then washed and analyzed immediately using a FACS-Canto II (BD Biosciences). To rule out excess cell death or apoptosis that can bias TMRM analysis, cells from four additional donors were stained with 7AAD-PerCP-Cy5 and Annexin V-FITC along with TMRM, CD34-APC, and CD90-APC-Cy7 and analyzed as detailed. 
| Colony forming unit (CFU) assays
| Statistical analysis
Results are expressed as the mean ± SD or mean ± SEM of varying numbers of individual experiments. Statistical differences were evaluated using the Student's t test for comparisons between two groups, whereas two-way ANOVA was used for comparisons between multiple groups.
Statistical significance was defined as *P < .05; **P < .01; ***P < .001.
3 | RESULTS
| Addition of VPA to a combination of cytokines limits cell proliferation but maintains cell viability
CD34+ cells derived from either adult mPB or ABM were incubated in serum-free media supplemented with the cytokines for 16 hours (cytokine priming) followed by addition of VPA (1 mM) and incubation for additional 7 days. Cells cultured with cytokines alone during the entire 16-hour-plus 7-day period were used as control. A schema of the culture system employed in this study is illustrated in Figure 1A .
This culture system has been previously optimized, using initially fresh 8 and subsequently cryopreserved 10 UCB, and has been evaluated using different chromatin modifying agents, of which VPA emerged as the most potent. 8 The viability of mPB and ABM cells treated with VPA and cytokines for 7 days, each exceeded 94%
( Figure 1B and Table 1 ). Cultures containing cytokines alone generated greater numbers of TNCs than cultures containing cytokines and VPA. The numbers of TNCs generated in VPA-containing mPB cultures were 6.7-fold (day 3) and 55-fold (day 7) greater than the number of cells used to initiate the cultures ( Figure 1C and Table 1 ).
ABM-derived CD34+ cells displayed a more delayed pattern of proliferation regardless of VPA treatment. Yet, there was a 3.8-fold expansion of TNCs by day 3 and 37-fold by day 7 in the cultures treated with VPA ( Figure 1D and Table 2 ).
| VPA expands phenotypically defined HSCs from both mPB and ABM
VPA-treated cultures contained a higher percentage of CD34+ cells throughout the culture period and led to a greater expansion of the 
| VPA treatment preserves functional characteristics of HSC activity
Since the phenotype of cells expanded ex vivo does not always correlate with function, we used aldehyde dehydrogenase (ALDH) activity as a functional marker of HSCs. 13, 14 The CD34+ population within VPA-expanded mPB cultures displayed significantly greater numbers of cells with detectable ALDH activity as compared to uncultured CD34+ cells and CD34+ cells within control cultures, after both 3 and 7 days of incubation ( Figure 4A and Figure S2A ; Table 1 ). Moreover, VPA treatment led to a 140-fold expansion in the absolute number of CD34+ALDH+ cells by day 7, vs 11-fold under control conditions (P < .01) ( Figure 4B ).
Functional HSCs rely heavily on glycolysis for energy production and generate low levels of reactive oxygen species (ROS). [15] [16] [17] [18] [19] [20] We have previously shown that VPA-expanded UCB-CD34+ cells exhibit a remodeled primitive mitochondrial network characterized by a low mitochondrial membrane potential, mass, and ROS generation. 21 We 
| VPA treatment increases the numbers of assayable hematopoietic progenitor cells
To further evaluate the function of HSCs generated in VPA-treated mPB-CD34+ cell cultures, the resulted cells were tested for their ability to generate CFUs. VPA-treated cells generated a 16-fold greater number of total CFUs, as compared to PCs and slightly higher than that generated by cells from the control cultures. Similarly, the fraction of assayable CFU-GEMM derived colonies was comparable between the VPA-treated and control cultures, but was significantly higher than those detected in PCs. Interestingly, among the CFU-GEMM generated by the VPA-treated cultures, a significantly greater number of large colonies with multiple foci, herein referred to as CFU-GEMM clusters, were observed as compared to both PCs and control cultures ( Figure 4F ). Identical observations were detected in cultures initiated with ABM-derived cultures (Table S1 ), suggesting that the cells generated in the presence of VPA have greater multipotent potential. To further support HSC activity within VPAtreated cultures, single CFU-GEMM colonies from control and VPA cultures from two mPB donors were plucked and replated. CFU-GEMMs from VPA-treated cultures generated a significantly higher number of secondary CFUs ( Figure 4G ).
| Grafts from VPA-treated cultures are capable of multilineage engraftment in NSG mice
To evaluate the functional behavior of the expanded HSCs in vivo, we transplanted the progeny of 2 × 10 5 mPB-or ABM-CD34+ cells cultured with or without VPA, into sublethally irradiated NSG mice. Figure 5A ; Table 1 ). Importantly, human cells belonging to both myeloid and lymphoid lineages were observed with a lineage distribution similar to that observed with PCs (CD34+, CD33+, CD15+, CD41a, glycophorin A+, CD19+, and CD3+ cells) in the marrows ( Figure 5C ), spleens ( Figure 5D Figure 5B ; Table 2 ). Moreover, the average human chimerism in grafts from VPA-treated cultures exceeded that of the unmanipulated PCs (3.5% vs 0.8%, P < .001). Human cells detected in these mice belonged to both myeloid and lymphoid lineages without a significant degree of lineage bias as compared to that observed with PCs ( Figure 5E ).
| Effect of VPA on HSCs from adult sources is comparable to that observed with UCB
To evaluate the effects triggered by VPA toward different ontogenic sources of HSCs, we collected published 8, 10, 21 and unpublished data from studies performed in our laboratory with UCB-CD34+ cells and compared it to our findings with ABM and mPB (Table S1 ). The fold expansion of TNCs and of the various subpopulations studied was greatest with UCB as compared to mPB; the expansion of mPB Recently, the cellular metabolic state has emerged as a reliable determinant of stem cell activity. 15 Low mitochondrial activity has been shown to correlate with long-term repopulating capacity and mark selfrenewing HSCs. [16] [17] [18] [19] [20] We have previously shown in UCB-HSCs that VPA treatment leads to a decrease in mitochondrial mass (as assayed by both Mitogreen dye and the ratio of mitochondrial to nuclear DNA), membrane potential (as assayed by TMRM), oxygen consumption, and production of ROS. 21 We used the TMRM assay (in both the presence and absence of verapamil) to functionally evaluate of the effects of VPA on adult HSCs, and the findings were comparable under these experimental conditions. The significant reduction in mitochondrial membrane potential observed in CD34+ cells generated in VPA-treated cultures as compared to control cultures suggests that these cells pos- A growing body of evidence supports the role of chromatin modifying agents, 22, 23, 29, 30 and specifically VPA in epigenetic reprogramming of human HSCs during ex vivo culture. Treatment of UCB as well as adult HCSs with VPA was associated with increased histone H4 acetylation at regulatory sites of genes implicated in HSC activity and self-renewal including HOXB4, AC133, CXCR4, GATA2, EZH2, and BMI1. [31] [32] [33] The inhibition of HDAC3, a target of VPA, recapitulated the VPA effects on HSC ex vivo expansion and resulted in a dramatic expansion of CD34+ cell numbers. 34 We have previously shown that VPA treatment of UCB-CD34+ upregulates the pluripotency genes SOX2, OCT4, and NANOG and their downstream targets. 8 Recently, we confirmed that the cellular reprogramming in UCB-CD34+ cells occurs shortly (24-48 hours) after exposure to VPA and is accompanied not only by phenotypic and transcriptomic changes but also by remodeling of the mitochondrial profile and suppression of ROS. 21 In this study, the early "phenotypic switch" and the changes in ALDH activity and mitochondrial membrane potential induced by VPA were highly comparable to our observations in UCB 8, 10, 21 and are suggestive of cellular reprogramming in CD34+ cells from adult sources. Few studies directly compared ex vivo culture of HSCs from different ontogenic sources. [2] [3] [4] 31 In the present study, we demonstrate that VPA exerts similar effects on mPB and ABM-CD34+ cells with those observed in ex vivo expansion of UCB-CD34+cells. These similarities suggest that common biological effects are achieved with VPA irrespective of whether the primary CD34+ cells were derived from adult tissues or UCB. Our findings are corroborated by a recent study that identified VPA as a significant enhancer of the number phenotypic and functional HSCs in a small molecule screen using a zebrafish embryo model. 35 This study also indicated that VPA increased human mPB-CD34+ cell adhesion to mesenchymal stromal cells, thus providing another putative mechanism for VPA's ability to positively affect the HSC function.
Despite an inconsistent correlation between phenotype and function in studies evaluating the ex vivo expansion of human HSCs, 28 several studies have shown a strong association between the CD34+ CD45RA-CD90+ phenotype, and specifically CD90 (Thy1) expression, and the long-term repopulating capacity in vivo. 36, 37 In the present study, VPA treatment led to a robust generation of a CD34+CD45RA-CD90+ cell population that correlated with HSC activity in functional studies and long-term repopulating capacity in vivo. In contrast, the lack of generation of phenotypically defined HSC subpopulations observed with cytokines alone control cultures correlated with poor engraftment outcomes under these culture conditions. Since the VPAtreated grafts retained the ability to engraft and support multilineage hematopoietic reconstitution, 16 weeks after their transplantation, we conclude that this cell product contains fully functional HSCs. To confirm that such a strategy led to an actual expansion of fully functional HSCs would require serial transplantation studies as well as HSC quantitation using limited dilution analyses that were beyond the scope of these studies. Nevertheless, the preservation of HSC function after a 16 hour-and 7-day cytokine containing culture, including multilineage hematopoietic reconstitution in vivo, is of key importance to the potential application of this culture strategy to gene modification protocols. Since the genetic modification of autologous HSCs requires cytokine stimulation, which often results in HSC differentiation with a significant loss of gene-modified cells with longterm repopulating capacity, we hypothesize that adding VPA to such cultures could avoid HSC exhaustion and allow for increased efficiency of the transduction process. This hypothesis is supported by a recently published study demonstrating increased efficiency of lentiviral transduction and elimination of lentiviral-induced myeloid bias by VPA treatment of human UCB-CD34+ cells. 38 
| CONCLUSION
We have shown that VPA is capable of promoting the ex vivo expansion of the numbers of phenotypically and functionally defined adult mPB and ABM HSCs, with maintenance of their in vivo reconstitution potential. These VPA-expanded grafts when transplanted into immune-deficient mice were able to give rise to human cells belonging to all lineages, including T cells. The effects of VPA were evident as early as after 3 days of culture, a time point relevant to gene modification protocols. These results strongly support that a VPA-based strategy might prove useful for genetic modification of human adult HSCs.
